» Articles » PMID: 22994610

End-stage Renal Disease and Dialysis in HIV-positive Patients: Observations from a Long-term Cohort Study with a Follow-up of 22 Years

Overview
Journal HIV Med
Publisher Wiley
Date 2012 Sep 22
PMID 22994610
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Renal disease is a common and serious complication in HIV-infected patients.

Methods: A retrospective cohort analysis for the period 1989-2010 was carried out to determine the prevalence, incidence and risk factors for end-stage renal disease (ESRD). ESRD was defined as initiation of renal replacement therapy. Three time periods were defined: 1989-1996 [pre-highly active antiretroviral therapy (HAART)], 1997-2003 (early HAART) and 2004-2010 (late HAART).

Results: Data for 9198 patients [78.2% male; 88.9% Caucasian; cumulative observation time 68 084 patient-years (PY)] were analysed. ESRD was newly diagnosed in 35 patients (0.38%). Risk factors for ESRD were Black ethnicity [relative risk (RR) 5.1; 95% confidence interval (CI) 2.3-10.3; P < 0.0001], injecting drug use (IDU) (RR 2.3; 95% CI 1.1-4.6; P = 0.02) and hepatitis C virus (HCV) coinfection (RR 2.2; 95% CI 1.1-4.2; P = 0.03). The incidence of ESRD decreased in Black patients over the three time periods [from 788.8 to 130.5 and 164.1 per 100 000 PY of follow-up (PYFU), respectively], but increased in Caucasian patients (from 29.9 to 41.0 and 43.4 per 100 000 PYFU, respectively). The prevalence of ESRD increased over time and reached 1.9 per 1000 patients in 2010. Mortality for patients with ESRD decreased nonsignificantly from period 1 to 2 (RR 0.72; P = 0.52), but significantly from period 1 to 3 (RR 0.24; P = 0.006), whereas for patients without ESRD mortality decreased significantly for all comparisons. ESRD was associated with a high overall mortality (RR 9.9; 95% CI 6.3-14.5; P < 0.0001).

Conclusion: As a result of longer survival, the prevalence of ESRD is increasing but remains associated with a high mortality. The incidence of ESRD declined in Black but not in Caucasian patients. IDU and HCV were identified as additional risk factors for the development of ESRD.

Citing Articles

The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis.

Gupta S, Friedman A, Desta Z AIDS. 2025; 39(4):356-361.

PMID: 39761595 PMC: 11864889. DOI: 10.1097/QAD.0000000000004071.


Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act.

Motter J, Hussain S, Brown D, Florman S, Rana M, Friedman-Moraco R Transplantation. 2023; 108(3):759-767.

PMID: 38012862 PMC: 11037099. DOI: 10.1097/TP.0000000000004857.


Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium.

Durand C, Martinez N, Neumann K, Benedict R, Baker A, Wolfe C Lancet Reg Health Am. 2023; 24:100553.

PMID: 37600163 PMC: 10435840. DOI: 10.1016/j.lana.2023.100553.


Analysis of HIV quasispecies and virological outcome of an HIV D+/R+ kidney-liver transplantation.

Rozera G, Visco-Comandini U, Giombini E, Santini F, Forbici F, Berno G Virol J. 2022; 19(1):4.

PMID: 34991646 PMC: 8739652. DOI: 10.1186/s12985-021-01730-w.


Science Over Stigma: Lessons and Future Direction of HIV-to-HIV Transplantation.

Klitenic S, Levan M, Van Pilsum Rasmussen S, Durand C Curr Transplant Rep. 2021; 8(4):314-323.

PMID: 34812403 PMC: 8600909. DOI: 10.1007/s40472-021-00345-y.